Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results

Ziopharm Oncology (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced its financial results for the fourth quarter and year ended December 31, 2017, and provided an update on the Company’s recent activities.

As quoted in the press release:

“This is an exciting year for Ziopharm and the clinical development of our two platform technologies, Controlled IL-12 and Sleeping Beauty,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. “With Sleeping Beauty, we achieved major milestones in 2017 and are looking forward to what is ahead in 2018. We plan to move our point-of-care technology into the clinic and, for the first time ever, we intend to infuse patients with T cells genetically modified and manufactured without virus using the Sleeping Beauty platform within two days from harvesting the T cells from patients. Also, Sleeping-Beauty-modified T-cell receptors targeting neoantigens – the very mutations that cause solid tumors – will enter the clinic with Dr. Steven Rosenberg’s team at the National Cancer Institute.”

Click here to read the full press release.